SMARCA4 and lung cancer: In summary, our study identified ROCK kinases as critical mediators of metabolic adaptation of cancer cells to OXPHOS inhibition and provides a strong preclinical basis for pursuing ROCK inhibitors as novel combination partners to OXPHOS inhibitors in SMARCA4-mutant lung cancer treatment.